Lazard Asset Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

A detailed history of Lazard Asset Management LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 18,714 shares of RARE stock, worth $849,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,714

Previous 37 50478.38%

Holding current value

$849,615

Previous $1,000 103800.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $751,002 - $1.11 Million	18,677 Added 50478.38%	18,714 $1.04 Million
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $154,282 - $212,788	-4,123 Reduced 99.11%	37 $1,000
Q1 2024 May 14, 2024	BUY	$43.02 - $53.69 $104,667 - $130,627	2,433 Added 140.88%	4,160 $193,000
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $55,939 - $86,721	-1,763 Reduced 50.52%	1,727 $82,000
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $66,348 - $88,654	1,900 Added 119.5%	3,490 $124,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $49,302 - $68,838	-1,320 Reduced 45.36%	1,590 $73,000
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $12,280 - $16,171	332 Added 12.88%	2,910 $115,000
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $9,407 - $12,926	279 Added 12.14%	2,578 $119,000
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $54,585 - $90,347	1,366 Added 146.41%	2,299 $95,000
Q2 2022 Aug 09, 2022	BUY	$45.8 - $85.4 $1,694 - $3,159	37 Added 4.13%	933 $54,000
Q1 2022 May 13, 2022	BUY	$62.2 - $84.4 $14,928 - $20,256	240 Added 36.59%	896 $64,000
Q4 2021 Feb 09, 2022	BUY	$73.71 - $87.86 $8,624 - $10,279	117 Added 21.71%	656 $54,000
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $77,920 - $102,400	-1,000 Reduced 64.98%	539 $48,000
Q2 2021 Aug 12, 2021	BUY	$92.19 - $115.71 $73,383 - $92,105	796 Added 107.13%	1,539 $145,000
Q4 2020 Feb 11, 2021	BUY	$84.4 - $177.39 $1,350 - $2,838	16 Added 2.2%	743 $102,000
Q3 2020 Nov 13, 2020	SELL	$72.98 - $90.0 $25,834 - $31,860	-354 Reduced 32.75%	727 $59,000
Q2 2020 Aug 13, 2020	SELL	$46.91 - $78.22 $35,370 - $58,977	-754 Reduced 41.09%	1,081 $84,000
Q1 2020 May 14, 2020	BUY	$33.8 - $62.9 $47,353 - $88,122	1,401 Added 322.81%	1,835 $81,000
Q4 2019 Feb 13, 2020	BUY	$36.08 - $45.83 $6,458 - $8,203	179 Added 70.2%	434 $18,000
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $1.02 Million - $1.51 Million	-23,970 Reduced 98.95%	255 $10,000
Q1 2017 Aug 13, 2019	SELL	N/A	-525 Reduced 2.12%	24,225 $1.64 Million
Q1 2016 Jul 25, 2019	SELL	N/A	-840 Reduced 3.28%	24,750 $1.57 Million
Q4 2015 Jul 24, 2019	SELL	N/A	-2,060 Reduced 7.45%	25,590 $2.87 Million
Q3 2015 Jul 15, 2019	BUY	N/A	27,650	27,650 $2.66 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.18B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Ultragenyx Pharmaceutical Inc. Transaction History